Your browser is no longer supported. Please, upgrade your browser.
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.86 Insider Own0.40% Shs Outstand68.61M Perf Week-5.01%
Market Cap3.64B Forward P/E- EPS next Y-4.74 Insider Trans-18.91% Shs Float60.16M Perf Month0.25%
Income-358.70M PEG- EPS next Q-1.37 Inst Own- Short Float12.47% Perf Quarter32.65%
Sales174.80M P/S20.83 EPS this Y-13.80% Inst Trans0.39% Short Ratio10.24 Perf Half Y8.91%
Book/sh9.11 P/B5.81 EPS next Y0.40% ROA-45.20% Target Price65.09 Perf Year15.86%
Cash/sh7.68 P/C6.89 EPS next 5Y40.00% ROE-63.90% 52W Range27.77 - 56.74 Perf YTD10.79%
Dividend- P/FCF- EPS past 5Y-34.00% ROI- 52W High-6.78% Beta2.14
Dividend %- Quick Ratio8.30 Sales past 5Y12.50% Gross Margin99.10% 52W Low90.47% ATR2.35
Employees536 Current Ratio8.40 Sales Q/Q188.40% Oper. Margin- RSI (14)54.87 Volatility3.77% 4.89%
OptionableYes Debt/Eq0.00 EPS Q/Q63.20% Profit Margin- Rel Volume0.41 Prev Close53.36
ShortableYes LT Debt/Eq0.00 EarningsApr 30 BMO Payout- Avg Volume732.42K Price52.90
Recom1.90 SMA202.80% SMA508.15% SMA20021.59% Volume300,934 Change-0.86%
Mar-04-20Initiated Barclays Equal Weight $50
Nov-26-19Initiated Cantor Fitzgerald Overweight $64
Sep-23-19Upgrade Guggenheim Neutral → Buy $55
May-23-19Resumed Goldman Neutral $55
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Jul-10-20 07:16AM  
Jul-02-20 06:08AM  
Jun-19-20 01:21AM  
Jun-18-20 12:00PM  
Jun-17-20 04:01PM  
Jun-12-20 04:23PM  
Jun-10-20 11:30AM  
Jun-09-20 11:29AM  
Jun-08-20 04:01PM  
May-30-20 11:31AM  
May-29-20 08:00AM  
May-28-20 11:56AM  
May-21-20 11:30AM  
May-19-20 07:00AM  
May-14-20 09:41AM  
May-13-20 05:01PM  
May-12-20 06:00PM  
May-07-20 10:18AM  
May-03-20 08:14AM  
May-01-20 08:10AM  
Apr-30-20 09:05AM  
Apr-23-20 12:32PM  
Apr-16-20 07:00AM  
Apr-15-20 09:01AM  
Apr-14-20 04:57PM  
Mar-30-20 04:01PM  
Mar-27-20 03:50PM  
Mar-25-20 04:01PM  
Mar-24-20 01:08PM  
Mar-23-20 07:00AM  
Mar-14-20 11:30AM  
Mar-03-20 09:05AM  
Feb-19-20 07:59AM  
Feb-18-20 07:00AM  
Feb-14-20 11:04AM  
Feb-13-20 08:55AM  
Feb-11-20 07:00AM  
Feb-06-20 12:31PM  
Feb-05-20 06:29AM  
Jan-30-20 07:00AM  
Jan-17-20 12:19PM  
Jan-08-20 11:26AM  
Jan-07-20 12:00PM  
Dec-23-19 07:00AM  
Dec-17-19 10:08AM  
Dec-16-19 04:00PM  
Dec-13-19 08:40AM  
Dec-09-19 04:19PM  
Dec-08-19 09:00AM  
Dec-02-19 07:00AM  
Nov-28-19 08:10AM  
Nov-25-19 07:00AM  
Nov-22-19 04:00PM  
Nov-17-19 08:42AM  
Nov-14-19 07:11AM  
Nov-13-19 10:21AM  
Nov-07-19 09:17PM  
Nov-06-19 04:01PM  
Nov-01-19 12:07PM  
Oct-31-19 08:55AM  
Oct-30-19 07:22PM  
Oct-27-19 11:50AM  
Oct-24-19 10:32AM  
Oct-17-19 07:00AM  
Oct-09-19 07:00AM  
Oct-02-19 12:00PM  
Sep-30-19 10:30AM  
Sep-10-19 07:00AM  
Sep-04-19 07:12PM  
Aug-31-19 09:32AM  
Aug-29-19 04:05PM  
Aug-15-19 10:30AM  
Aug-09-19 09:24AM  
Aug-05-19 11:15PM  
Aug-01-19 12:02PM  
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bowden ChristopherChief Medical OfficerMay 20Option Exercise35.163,583125,97811,889May 21 05:05 PM
Bowden ChristopherChief Medical OfficerMay 20Sale50.013,583179,2008,306May 21 05:05 PM
Alenson CarmanPrincipal Accounting OfficerMar 02Sale47.3034516,319184Mar 04 05:08 PM
Alenson CarmanPrincipal Accounting OfficerFeb 26Sale47.1247222,241184Feb 28 04:17 PM
Alenson CarmanPrincipal Accounting OfficerFeb 20Sale53.372,427129,529184Feb 24 04:02 PM
Bowden ChristopherChief Medical OfficerFeb 13Option Exercise35.167,100249,6368,750Feb 18 04:05 PM
Bowden ChristopherChief Medical OfficerFeb 13Sale50.167,100356,1121,650Feb 18 04:05 PM
Bowden ChristopherChief Medical OfficerFeb 11Option Exercise35.1662121,8342,271Feb 13 04:21 PM
Bowden ChristopherChief Medical OfficerFeb 11Sale50.0262131,0631,650Feb 13 04:21 PM
Bowden ChristopherChief Medical OfficerFeb 05Option Exercise35.1635,4471,246,31737,097Feb 06 04:52 PM
Bowden ChristopherChief Medical OfficerFeb 04Option Exercise35.168,526299,77415,841Feb 06 04:52 PM
Bowden ChristopherChief Medical OfficerFeb 04Sale50.0849,6382,485,9891,650Feb 06 04:52 PM
Alenson CarmanPrincipal Accounting OfficerDec 26Sale50.092,950147,766184Dec 30 04:08 PM
FOUSE JACQUALYN AChief Executive OfficerNov 13Buy31.0040,3221,249,98241,722Nov 15 04:05 PM
Schenkein David PDirectorNov 13Buy31.008,064249,98497,567Nov 15 04:03 PM
CELGENE CORP /DE/10% OwnerNov 12Buy31.00403,22512,499,9751,777,824Nov 14 04:06 PM